Advertisement

Synthesis and Analgesic Activity of [b]-Annelated 4-Quinolones

  • A. A. BotevaEmail author
  • I. V. Fefilova
  • G. A. Triandafilova
  • V. V. Maslova
  • S. Yu. Solodnikov
  • O. P. Krasnykh
Article
  • 4 Downloads

Considering the side effects of existing drugs used for pain relief, the search for new analgesics with high efficacy and safety remains relevant. Aseries of imidazopyrrolo[3,4-b]quinoline-5,11-diones and pyrimidopyrrolo[3,4-b]quinoline-6,12-diones II were synthesized, whose analgesic activity at a dose of 0.05 mmol/kg was studied in the hotplate test in rats after i.p. administration. One compound was found with analgesic activity comparable to that of reference compound diclofenac sodium. Compounds II were less toxic than diclofenac sodium.

Keywords

[b]-annelated 4-quinolones analgesic activity antinociceptive action 

References

  1. 1.
    O. V. Kolokolov, I. V. Sitkali, and A. M. Kolokolova, Ros. Med. Zh., 12, 664 – 667 (2015).Google Scholar
  2. 2.
    N. Henschke, S. J. Kamper, and C. G. Maher, Mayo. Clin. Proc., 90, No. 1, 139 – 147 (2015).CrossRefGoogle Scholar
  3. 3.
    A. B. Danilov and A. B. Danilov, Ros. Zh. Boli, 2, 35 – 39 (2010).Google Scholar
  4. 4.
    G. T. Carter, V. Duong, S. Ho, et al., Phys. Med. Rehabil. Clin. N. Am. 25(2), 457 – 470 (2014).CrossRefGoogle Scholar
  5. 5.
    C. Mattia and F. Coluzzi, Minerva Anestesiol., 71(7 – 8), 461 – 470 (2005).Google Scholar
  6. 6.
    C. K. S. Ong, P. Lirk, C. H. Tan, and R. A. Seymour, Clin. Med. Res., 5(1), 19 – 34 (2007).Google Scholar
  7. 7.
    J.-M. Dogné, C. T. Supuran, and D. Pratico, J. Med. Chem., 48(7), 2251 – 2257 (2005).CrossRefGoogle Scholar
  8. 8.
    R. Benyamin, A. M. Trescot, and S. Datta, Pain Physician., 11 (2 Suppl.), 105 – 120 (2008).Google Scholar
  9. 9.
    D. G. Brown, R. A. Urbanek, M. Murphy, et. al., PatentWO02 / 26740 A1 (2002).Google Scholar
  10. 10.
    D. G. Brown, R. A. Urbanek, T. M. Bare, et al., Bioorg. Med. Chem. Let., 13, 3553 – 3556 (2003).CrossRefGoogle Scholar
  11. 11.
    K. Kawamura, S. Mihara, S. Nukui, and C. Uchida, European patent No. 1310498 (2003); Bul. 20 (2003).Google Scholar
  12. 12.
    K. T. Velázquez, H. Mohammad, and S. M. Sweitzer, Pharmacol. Res.: Official J. Italian Pharmacol. Soc., 55(6), 578 – 589 (2007).Google Scholar
  13. 13.
    F. Bu, H. Tian, S. Gong, Q. Zhu, et al., Sci Rep., 5, 1 – 11 (2015).Google Scholar
  14. 14.
    A. A. Boteva, O. P. Krasnykh, I. V. Fefilova, E. B. Babushkina, et al., Izv. Akad. Nauk. Ser. Khim., 3, 731 – 738 (2014).Google Scholar
  15. 15.
    European Convention for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes, ETS 123, Strasbourg (1986).Google Scholar
  16. 16.
    Directive 2010 / 63 / EU of the European Parliament and of the Council, Official. Eur. Union, L 276 (2010).Google Scholar
  17. 17.
    Guidelines for Preclinical Studies of Medicines [in Russian], A. N. Mironov (ed.), Grif i K, Moscow (2012), Chapter 1, pp. 197 – 219.Google Scholar
  18. 18.
    OECD Guidelines for the Testing of chemicals, 423, OEÑD, Paris (2001), p. 4.Google Scholar
  19. 19.
    K. K. Sidorov, Toxicology of New Industrial Substances [inRussian], Moscow (1973), Vol. 13, pp. 47 – 51.Google Scholar
  20. 20.
    V. É. Kolla and B. Ya. Syropyatov, Doses of Drugs and Chemical Compounds for Rational Use [in Russian], Meditsina, Moscow (1998).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. A. Boteva
    • 1
    Email author
  • I. V. Fefilova
    • 1
  • G. A. Triandafilova
    • 1
  • V. V. Maslova
    • 1
  • S. Yu. Solodnikov
    • 1
  • O. P. Krasnykh
    • 1
  1. 1.Science Education Center for Applied Chemical and Biological ResearchPerm National Research Polytechnical UniversityPermRussia

Personalised recommendations